gabapentin has been researched along with Postherpetic Neuralgia in 85 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of gastroretentive gabapentin (G-GR) and describe relationships among pain quality, pain impact, and overall-improvement scores in patients with postherpetic neuralgia (PHN)." | 9.20 | Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin. ( Backonja, MM; Freeman, R; Sweeney, M; Wallace, MS, 2015) |
| "To understand how patient demographics and patient-reported disease characteristics relate to successful management of postherpetic neuralgia (PHN), integrated data from phase 3 and phase 4 studies of patients with PHN (n = 546) who received once-daily gastroretentive gabapentin (G-GR, 1800 mg) were analyzed." | 9.20 | Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes. ( Bucior, I; Kantor, D; Panchal, S; Patel, V; Rauck, R, 2015) |
| "This study evaluated the long-term safety and tolerability of a gastroretentive formulation of gabapentin (G-GR) and its effect on weight gain in postherpetic neuralgia (PHN) patients participating in a 14-week, open-label extension to a 10-week double-blind study." | 9.17 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| "The objectives of this study were to identify and determine the validity of early decision criteria following once-daily gastroretentive gabapentin (G-GR) treatment in patients with postherpetic neuralgia (PHN)." | 9.16 | Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia. ( Hsu, PH; Jensen, MP; Vanhove, GF, 2012) |
| "The efficacy of gabapentin in some patients with postherpetic neuralgia (PHN) may be limited by suboptimal drug exposure from unpredictable and saturable absorption." | 9.15 | Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. ( Backonja, MM; Canafax, DM; Cundy, KC, 2011) |
| "One hundred fifty-eight patients with moderate-to-severe postherpetic neuralgia were randomly assigned to 1 of 3 treatment conditions: (1) extended release gabapentin (G-ER) 1800 mg once-daily administered in the evening; (2) G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM); or (3) placebo G-ER." | 9.14 | Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. ( Chiang, YK; Jensen, MP; Wu, J, 2009) |
| "The study aims to systematically evaluate the clinical effect of gabapentin in the treatment of postherpetic neuralgia (PHN)." | 8.98 | A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. ( Dai, ZG; Gao, CX; Li, L; Ma, KT; Si, JQ; Wang, S; Zhang, M, 2018) |
| "Gabapentin, extended-release gabapentin (gabapentin ER), and gabapentin enacarbil (GEn), play an important role in relieving pain associated with postherpetic neuralgia (PHN)." | 8.95 | Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. ( Wang, J; Zhu, Y, 2017) |
| "Neurontin®, an immediate-release (IR) formulation of gabapentin, was the first drug approved by the United States Food and Drug Administration for the treatment of postherpetic neuralgia (PHN)." | 8.89 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| "Gabapentin immediate-release formulations (G-IR) administered three times a day is an efficacious treatment for postherpetic neuralgia (PHN), but its potential benefits may not be fully realized due to tolerability issues as well as its pharmacokinetic (PK) properties such as its short half-life, and regional and saturable absorption in the proximal small intestine." | 8.88 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| "The purpose of this study was to compare the cost effectiveness of a new 8% capsaicin patch, compared to the current treatments for postherpetic neuralgia (PHN), including tricyclic antidepressants (TCAs), topical lidocaine patches, duloxetine, gabapentin, and pregabalin." | 8.87 | Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. ( Armstrong, EP; Malone, DC; McCarberg, B; Panarites, CJ; Pham, SV, 2011) |
| "To evaluate the safety and effectiveness of once-daily gastroretentive gabapentin (G-GR) for the treatment of postherpetic neuralgia in real-world clinical practice." | 7.81 | Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). ( Dunteman, ED; Kareht, S; Markley, HG; Sweeney, M, 2015) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 7.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster." | 7.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "Although both gabapentin and pregabalin are first-line drugs for neuropathic pain including postherpetic neuralgia (PHN), no report has directly compared the magnitude of pain relief and the incidence of side effects of both drugs." | 7.77 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin." | 7.76 | Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. ( Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Puenpatom, RA; Summers, KH; Wei, R, 2010) |
| "Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice." | 7.74 | A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. ( Gore, M; Sadosky, A; Stacey, B; Tai, KS, 2007) |
| "This study set out to assess the cost effectiveness of using a 5% lidocaine (lignocaine) medicated plaster for the treatment of postherpetic neuralgia (PHN) compared with gabapentin, pregabalin 300 mg/day or 600 mg/day in German primary care." | 7.74 | Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. ( Dakin, H; Gabriel, A; Hertel, N; Liedgens, H; Mitchell, S; Nautrup, BP; Nuijten, M, 2008) |
| "The aim of this study was to examine the 12-week cost-effectiveness of 2 treatments of NeP, pregabalin versus gabapentin, in managing diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) in a Canadian setting." | 7.73 | Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. ( Dukes, E; Gordon, A; Rousseau, C; Tarride, JE; Vera-Llonch, M, 2006) |
| "Gabapentin was initiated at 300 mg/day and gradually titrated to a maximum of 1800 mg/day." | 6.90 | Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial. ( Bulilete, O; Leiva, A; Llobera, J; Roca, A; Rullán, M, 2019) |
| "Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons." | 6.84 | Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. ( Bulilete, O; González-Bals, MJ; Leiva, A; Llobera, J; Lorente, P; Roca, A; Rullán, M; Soler, A, 2017) |
| "To characterize risk factors for occurrence of adverse events (AEs) and treatment discontinuations due to AEs for improving safety and tolerability of treatment of postherpetic neuralgia (PHN)." | 6.80 | Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin. ( Bucior, I; Nalamachu, S; Shaparin, N; Slattum, PW, 2015) |
| " The most frequently reported adverse events were dizziness (G-GR, 11%; placebo, 2%) and somnolence (G-GR, 5%; placebo, 3%)." | 6.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| " The most common (placebo/G-GR) adverse events (AEs) were dizziness (≥75: 3." | 6.78 | Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. ( Gupta, A; Li, S, 2013) |
| "Gabapentin ER was well tolerated in this study." | 6.75 | Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. ( Cowles, VE; Irving, G; Wallace, MS, 2010) |
| "Gabapentin was shown to be equally efficacious but was better tolerated compared to nortriptyline and can be considered a suitable alternative for the treatment of PHN." | 6.72 | Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. ( Chandra, K; Gupta, S; Malhotra, S; Pandhi, P; Shafiq, N, 2006) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 6.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Gabapentin was significantly more likely than placebo to lead patients to rate their global impression of change as "much improved" or "very much improved" (RR=1." | 6.50 | Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. ( Li, CL; Li, YW; Liang, R; Liu, Y; Meng, FY; Pan, LH; Qian, W; Zhang, LC; Zhu, M, 2014) |
| "Treatment with gabapentin 1800 mg/day yielded a significant reduction in PHN up to 14 weeks." | 6.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| "Gabapentin is a structural analog of gamma aminobutyric acid that binds to the α(2)-δ site of voltage-dependent calcium channels and modulates the influx of calcium, with a resulting reduction in excitatory neurotransmitter release." | 6.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| " The new drug combines generic gabapentin with a polymeric delivery system allowing for extended release and is licensed to be given only as a once-daily dosing regimen." | 6.47 | Extended-release gabapentin in post-herpetic neuralgia. ( Farquhar-Smith, P; Thomas, B, 2011) |
| "Desipramine was more effective and less expensive than gabapentin or pregabalin (dominant) under all conditions tested." | 6.44 | A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. ( Holloway, RG; Noyes, K; O'Connor, AB, 2007) |
| "Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter gamma-aminobutyric acid (GABA)." | 6.44 | Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. ( Striano, P; Striano, S, 2008) |
| "Early treatment of herpes zoster neuralgia is of great significance to reduce the incidence of PHN." | 5.72 | Effective treatment of high-voltage pulsed radiofrequency combined with oxygen-ozone injection in acute zoster neuralgia. ( Du, HY; Jia, LL; Li, LM; Yu, WL; Zhang, ZL; Zheng, BS, 2022) |
| " Suboptimal dosing and discontinuation may be associated with supplementary use of other analgesics, especially opioids." | 5.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| "To determine the effect of gastroretentive gabapentin (G-GR) and describe relationships among pain quality, pain impact, and overall-improvement scores in patients with postherpetic neuralgia (PHN)." | 5.20 | Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin. ( Backonja, MM; Freeman, R; Sweeney, M; Wallace, MS, 2015) |
| "To understand how patient demographics and patient-reported disease characteristics relate to successful management of postherpetic neuralgia (PHN), integrated data from phase 3 and phase 4 studies of patients with PHN (n = 546) who received once-daily gastroretentive gabapentin (G-GR, 1800 mg) were analyzed." | 5.20 | Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes. ( Bucior, I; Kantor, D; Panchal, S; Patel, V; Rauck, R, 2015) |
| "This study evaluated the long-term safety and tolerability of a gastroretentive formulation of gabapentin (G-GR) and its effect on weight gain in postherpetic neuralgia (PHN) patients participating in a 14-week, open-label extension to a 10-week double-blind study." | 5.17 | Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. ( Irving, G; Jensen, MP; Rauck, R; Sweeney, M; Vanhove, GF; Wallace, M, 2013) |
| "The objectives of this study were to identify and determine the validity of early decision criteria following once-daily gastroretentive gabapentin (G-GR) treatment in patients with postherpetic neuralgia (PHN)." | 5.16 | Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia. ( Hsu, PH; Jensen, MP; Vanhove, GF, 2012) |
| "The efficacy of gabapentin in some patients with postherpetic neuralgia (PHN) may be limited by suboptimal drug exposure from unpredictable and saturable absorption." | 5.15 | Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. ( Backonja, MM; Canafax, DM; Cundy, KC, 2011) |
| "One hundred fifty-eight patients with moderate-to-severe postherpetic neuralgia were randomly assigned to 1 of 3 treatment conditions: (1) extended release gabapentin (G-ER) 1800 mg once-daily administered in the evening; (2) G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM); or (3) placebo G-ER." | 5.14 | Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. ( Chiang, YK; Jensen, MP; Wu, J, 2009) |
| "The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain." | 5.01 | A Clinical Overview of Off-label Use of Gabapentinoid Drugs. ( Brett, AS; Goodman, CW, 2019) |
| "The study aims to systematically evaluate the clinical effect of gabapentin in the treatment of postherpetic neuralgia (PHN)." | 4.98 | A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. ( Dai, ZG; Gao, CX; Li, L; Ma, KT; Si, JQ; Wang, S; Zhang, M, 2018) |
| " Effective interventions were described for painful diabetic neuropathy (pregabalin, gabapentin, certain tricyclic antidepressants [TCAs], opioids, antidepressants, and anticonvulsants), postherpetic neuralgia (gabapentin, pregabalin, certain TCAs, antidepressants and anticonvulsants, opioids, sodium valproate, topical capsaicin, and lidocaine), lumbar radicular pain (epidural corticosteroids, repetitive transcranial magnetic stimulation [rTMS], and discectomy), cervical radicular pain (rTMS), carpal tunnel syndrome (carpal tunnel release), cubital tunnel syndrome (simple decompression and ulnar nerve transposition), trigeminal neuralgia (carbamazepine, lamotrigine, and pimozide for refractory cases, rTMS), HIV-related neuropathy (topical capsaicin), and central NeuP (certain TCAs, pregabalin, cannabinoids, and rTMS)." | 4.95 | Interventions for Neuropathic Pain: An Overview of Systematic Reviews. ( Biocic, M; Boric, K; Cavar, M; Dosenovic, S; Jelicic Kadic, A; Markovina, N; Miljanovic, M; Puljak, L; Vucic, K, 2017) |
| "Gabapentin, extended-release gabapentin (gabapentin ER), and gabapentin enacarbil (GEn), play an important role in relieving pain associated with postherpetic neuralgia (PHN)." | 4.95 | Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. ( Wang, J; Zhu, Y, 2017) |
| "Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Gabapentin is approved for the treatment of postherpetic neuralgia (PHN) and epilepsy." | 4.89 | The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery. ( Chen, C; Cowles, VE; Sweeney, M, 2013) |
| "Neurontin®, an immediate-release (IR) formulation of gabapentin, was the first drug approved by the United States Food and Drug Administration for the treatment of postherpetic neuralgia (PHN)." | 4.89 | Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. ( Chen, C; Cowles, VE; Han, CH; Sweeney, M, 2013) |
| "Gabapentin immediate-release formulations (G-IR) administered three times a day is an efficacious treatment for postherpetic neuralgia (PHN), but its potential benefits may not be fully realized due to tolerability issues as well as its pharmacokinetic (PK) properties such as its short half-life, and regional and saturable absorption in the proximal small intestine." | 4.88 | Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview. ( Argoff, CE; Chen, C; Cowles, VE, 2012) |
| "The purpose of this study was to compare the cost effectiveness of a new 8% capsaicin patch, compared to the current treatments for postherpetic neuralgia (PHN), including tricyclic antidepressants (TCAs), topical lidocaine patches, duloxetine, gabapentin, and pregabalin." | 4.87 | Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. ( Armstrong, EP; Malone, DC; McCarberg, B; Panarites, CJ; Pham, SV, 2011) |
| "Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate or severe neuropathic pain from postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN) is associated with pain reduction of at least 50% in 14% to 17% more patients than placebo." | 3.88 | Gabapentin for Chronic Neuropathic Pain. ( Derry, S; Moore, A; Wiffen, P, 2018) |
| "To evaluate the safety and effectiveness of once-daily gastroretentive gabapentin (G-GR) for the treatment of postherpetic neuralgia in real-world clinical practice." | 3.81 | Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN). ( Dunteman, ED; Kareht, S; Markley, HG; Sweeney, M, 2015) |
| " To address this issue, we obtained clinical trial data from the Food and Drug Administration (FDA) through the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership, and harmonized patient level data from 12 clinical trials (4 gabapentin and 8 pregabalin) in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN)." | 3.80 | Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. ( Dworkin, RH; Farrar, JT; Gilron, I; Haynes, K; Katz, NP; Kerns, RD; Rappaport, BA; Rowbotham, MC; Tierney, AM; Troxel, AB; Turk, DC, 2014) |
| "The analysis was based on a dynamic simulation model which estimated and compared the costs and outcomes of pregabalin and gabapentin in a hypothetical cohort of 1,000 patients suffering from painful Diabetic Peripheral Neuropathy (DPN) or Post-Herpetic Neuralgia (PHN)." | 3.79 | Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. ( Athanasakis, K; Karampli, E; Kyriopoulos, J; Lyras, L; Petrakis, I; Vitsou, E, 2013) |
| "To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster." | 3.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "Although both gabapentin and pregabalin are first-line drugs for neuropathic pain including postherpetic neuralgia (PHN), no report has directly compared the magnitude of pain relief and the incidence of side effects of both drugs." | 3.77 | Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. ( Hidaka, I; Ifuku, M; Inada, E; Iseki, M; Komatus, S; Morita, Y, 2011) |
| "To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin." | 3.76 | Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. ( Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Puenpatom, RA; Summers, KH; Wei, R, 2010) |
| "This study set out to assess the cost effectiveness of using a 5% lidocaine (lignocaine) medicated plaster for the treatment of postherpetic neuralgia (PHN) compared with gabapentin, pregabalin 300 mg/day or 600 mg/day in German primary care." | 3.74 | Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. ( Dakin, H; Gabriel, A; Hertel, N; Liedgens, H; Mitchell, S; Nautrup, BP; Nuijten, M, 2008) |
| "Both gabapentin and pregabalin are approved for the management of postherpetic neuralgia (PHN), although dosing and pharmacokinetic differences between these medications may affect their use in actual practice." | 3.74 | A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. ( Gore, M; Sadosky, A; Stacey, B; Tai, KS, 2007) |
| "Gabapentin is an antiepileptic drug approved for the treatment of postherpetic neuralgia and as adjunctive therapy for partial seizures." | 3.73 | Gabapentin-induced neurologic toxicities. ( Bookwalter, T; Gitlin, M, 2005) |
| "The aim of this study was to examine the 12-week cost-effectiveness of 2 treatments of NeP, pregabalin versus gabapentin, in managing diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) in a Canadian setting." | 3.73 | Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. ( Dukes, E; Gordon, A; Rousseau, C; Tarride, JE; Vera-Llonch, M, 2006) |
| "Postherpetic neuralgia is an annoying pain that mainly affects older people." | 3.01 | Therapeutic Strategies for Postherpetic Neuralgia: Mechanisms, Treatments, and Perspectives. ( Liu, C; Song, L; Tang, J; Zeng, A; Zhang, Y, 2023) |
| "Gabapentin was initiated at 300 mg/day and gradually titrated to a maximum of 1800 mg/day." | 2.90 | Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial. ( Bulilete, O; Leiva, A; Llobera, J; Roca, A; Rullán, M, 2019) |
| "Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons." | 2.84 | Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. ( Bulilete, O; González-Bals, MJ; Leiva, A; Llobera, J; Lorente, P; Roca, A; Rullán, M; Soler, A, 2017) |
| "To characterize risk factors for occurrence of adverse events (AEs) and treatment discontinuations due to AEs for improving safety and tolerability of treatment of postherpetic neuralgia (PHN)." | 2.80 | Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin. ( Bucior, I; Nalamachu, S; Shaparin, N; Slattum, PW, 2015) |
| " The most common (placebo/G-GR) adverse events (AEs) were dizziness (≥75: 3." | 2.78 | Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. ( Gupta, A; Li, S, 2013) |
| " The most frequently reported adverse events were dizziness (G-GR, 11%; placebo, 2%) and somnolence (G-GR, 5%; placebo, 3%)." | 2.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| "Gabapentin ER was well tolerated in this study." | 2.75 | Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. ( Cowles, VE; Irving, G; Wallace, MS, 2010) |
| "Gabapentin was shown to be equally efficacious but was better tolerated compared to nortriptyline and can be considered a suitable alternative for the treatment of PHN." | 2.72 | Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. ( Chandra, K; Gupta, S; Malhotra, S; Pandhi, P; Shafiq, N, 2006) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 2.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Gabapentin was significantly more likely than placebo to lead patients to rate their global impression of change as "much improved" or "very much improved" (RR=1." | 2.50 | Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials. ( Li, CL; Li, YW; Liang, R; Liu, Y; Meng, FY; Pan, LH; Qian, W; Zhang, LC; Zhu, M, 2014) |
| "Treatment with gabapentin 1800 mg/day yielded a significant reduction in PHN up to 14 weeks." | 2.50 | Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. ( Cao, H; Fan, H; Hu, X; Li, J; Shao, Y; Wang, J; Yu, W; Zhang, Q, 2014) |
| "Gabapentin is a structural analog of gamma aminobutyric acid that binds to the α(2)-δ site of voltage-dependent calcium channels and modulates the influx of calcium, with a resulting reduction in excitatory neurotransmitter release." | 2.48 | Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. ( Beal, B; Moeller-Bertram, T; Schilling, JM; Wallace, MS, 2012) |
| "Once established, postherpetic neuralgia is particularly difficult to treat, and is often resistant to conventional analgesics." | 2.47 | [Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia]. ( Takasaki, I, 2011) |
| " The new drug combines generic gabapentin with a polymeric delivery system allowing for extended release and is licensed to be given only as a once-daily dosing regimen." | 2.47 | Extended-release gabapentin in post-herpetic neuralgia. ( Farquhar-Smith, P; Thomas, B, 2011) |
| "Gabapentin is an antiepileptic drug (AED) by design expected to mimic the action of the neurotransmitter gamma-aminobutyric acid (GABA)." | 2.44 | Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. ( Striano, P; Striano, S, 2008) |
| "Desipramine was more effective and less expensive than gabapentin or pregabalin (dominant) under all conditions tested." | 2.44 | A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. ( Holloway, RG; Noyes, K; O'Connor, AB, 2007) |
| "Early treatment of herpes zoster neuralgia is of great significance to reduce the incidence of PHN." | 1.72 | Effective treatment of high-voltage pulsed radiofrequency combined with oxygen-ozone injection in acute zoster neuralgia. ( Du, HY; Jia, LL; Li, LM; Yu, WL; Zhang, ZL; Zheng, BS, 2022) |
| "To compare the therapeutic effects of continuous epidural block combined with drugs and oral drugs alone on postherpetic neuralgia (PHN)." | 1.62 | Comparison of therapeutic effects of continuous epidural nerve block combined with drugs on postherpetic neuralgia. ( Dong, X; Liu, Y; Liu, Z; Yang, Q; Zhang, Z, 2021) |
| "Chronic neuropathic pain often has a negative impact on the quality of life and is difficult to treat." | 1.56 | [Whether or not to use gabapentinoids in adults with chronic neuropathic pain]. ( El Houssein, L; Hollmann, MW; Kallewaard, J; Steegers, MAH; van Poelgeest, EP; Wartenberg, HCH, 2020) |
| " Suboptimal dosing and discontinuation may be associated with supplementary use of other analgesics, especially opioids." | 1.39 | Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. ( Becker, L; Halpern, R; Johnson, P; Sweeney, M, 2013) |
| "Amitriptyline was the only antidepressant prescribed commonly as a first-line treatment." | 1.39 | An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. ( Carroll, D; Gabriel, ZL; Hall, GC; McQuay, HJ; Morant, SV, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (20.00) | 29.6817 |
| 2010's | 58 (68.24) | 24.3611 |
| 2020's | 10 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, J | 1 |
| Li, M | 1 |
| Li, J | 2 |
| Han, H | 1 |
| Huang, J | 1 |
| Qin, H | 1 |
| Li, X | 1 |
| Tan, L | 1 |
| Xu, J | 1 |
| Peng, J | 1 |
| Zhang, E | 1 |
| Fei, Y | 1 |
| Xu, L | 1 |
| Huang, B | 1 |
| Yao, M | 1 |
| Li, LM | 1 |
| Zhang, ZL | 1 |
| Zheng, BS | 1 |
| Jia, LL | 1 |
| Yu, WL | 1 |
| Du, HY | 1 |
| Menaldi, SL | 1 |
| Halim, PA | 1 |
| Kurniawan, K | 1 |
| Tang, J | 1 |
| Zhang, Y | 1 |
| Liu, C | 1 |
| Zeng, A | 1 |
| Song, L | 1 |
| Dong, X | 1 |
| Liu, Y | 2 |
| Yang, Q | 1 |
| Liu, Z | 1 |
| Zhang, Z | 1 |
| Mathieson, S | 1 |
| Lin, CC | 1 |
| Underwood, M | 1 |
| Eldabe, S | 1 |
| van Poelgeest, EP | 1 |
| El Houssein, L | 1 |
| Kallewaard, J | 1 |
| Hollmann, MW | 1 |
| Steegers, MAH | 1 |
| Wartenberg, HCH | 1 |
| Liao, YM | 1 |
| Lu, HF | 1 |
| Xie, P | 1 |
| Zhao, Y | 1 |
| Han, Q | 1 |
| Zhang, QX | 1 |
| Zuo, XH | 1 |
| Si, YN | 1 |
| Bao, HG | 1 |
| Liu, F | 1 |
| Lu, GJ | 1 |
| Bai, ZY | 1 |
| Wiffen, PJ | 1 |
| Derry, S | 2 |
| Bell, RF | 1 |
| Rice, AS | 3 |
| Tölle, TR | 1 |
| Phillips, T | 1 |
| Moore, RA | 1 |
| Dosenovic, S | 1 |
| Jelicic Kadic, A | 1 |
| Miljanovic, M | 1 |
| Biocic, M | 1 |
| Boric, K | 1 |
| Cavar, M | 1 |
| Markovina, N | 1 |
| Vucic, K | 1 |
| Puljak, L | 1 |
| Moore, A | 1 |
| Wiffen, P | 1 |
| Zhang, M | 1 |
| Gao, CX | 1 |
| Ma, KT | 1 |
| Li, L | 1 |
| Dai, ZG | 1 |
| Wang, S | 1 |
| Si, JQ | 1 |
| Forstenpointner, J | 1 |
| Rice, ASC | 1 |
| Finnerup, NB | 1 |
| Baron, R | 2 |
| Ghanavatian, S | 1 |
| Wie, CS | 1 |
| Low, RS | 1 |
| Zhang, N | 1 |
| Montoya, JM | 1 |
| Dhaliwal, GS | 1 |
| Swanson, DL | 1 |
| Goodman, CW | 1 |
| Brett, AS | 1 |
| Bulilete, O | 2 |
| Leiva, A | 2 |
| Rullán, M | 2 |
| Roca, A | 2 |
| Llobera, J | 2 |
| Hall, GC | 1 |
| Morant, SV | 1 |
| Carroll, D | 1 |
| Gabriel, ZL | 1 |
| McQuay, HJ | 1 |
| Athanasakis, K | 1 |
| Petrakis, I | 1 |
| Karampli, E | 1 |
| Vitsou, E | 1 |
| Lyras, L | 1 |
| Kyriopoulos, J | 1 |
| Khadem, T | 1 |
| Stevens, V | 1 |
| Harden, RN | 1 |
| Kaye, AD | 2 |
| Kintanar, T | 1 |
| Argoff, CE | 4 |
| Gupta, A | 1 |
| Li, S | 1 |
| Meng, FY | 1 |
| Zhang, LC | 1 |
| Pan, LH | 1 |
| Zhu, M | 1 |
| Li, CL | 1 |
| Li, YW | 1 |
| Qian, W | 1 |
| Liang, R | 1 |
| Fan, H | 1 |
| Yu, W | 1 |
| Zhang, Q | 1 |
| Cao, H | 1 |
| Wang, J | 2 |
| Shao, Y | 1 |
| Hu, X | 1 |
| Farrar, JT | 1 |
| Troxel, AB | 1 |
| Haynes, K | 1 |
| Gilron, I | 2 |
| Kerns, RD | 1 |
| Katz, NP | 1 |
| Rappaport, BA | 1 |
| Rowbotham, MC | 1 |
| Tierney, AM | 1 |
| Turk, DC | 1 |
| Dworkin, RH | 2 |
| Markley, HG | 1 |
| Dunteman, ED | 1 |
| Kareht, S | 1 |
| Sweeney, M | 8 |
| Pickering, G | 1 |
| Johnson, RW | 1 |
| Ryan, NM | 1 |
| Hiom, S | 1 |
| Patel, GK | 1 |
| Newcombe, RG | 1 |
| Khot, S | 1 |
| Martin, C | 1 |
| Shaparin, N | 1 |
| Slattum, PW | 1 |
| Bucior, I | 3 |
| Nalamachu, S | 1 |
| Freeman, R | 1 |
| Wallace, MS | 4 |
| Backonja, MM | 2 |
| Kantor, D | 1 |
| Panchal, S | 1 |
| Patel, V | 1 |
| Rauck, R | 2 |
| Pi, ZB | 1 |
| Lin, H | 1 |
| He, GD | 1 |
| Cai, Z | 1 |
| Xu, XZ | 1 |
| Lee, EG | 1 |
| Lee, HJ | 1 |
| Hyun, DJ | 1 |
| Min, K | 1 |
| Kim, DH | 1 |
| Yoon, MS | 1 |
| Hadley, GR | 1 |
| Gayle, JA | 1 |
| Ripoll, J | 1 |
| Jones, MR | 1 |
| Kaye, RJ | 1 |
| Mehta, N | 1 |
| Bujanover, S | 1 |
| Shah, R | 1 |
| Gulati, A | 1 |
| Zhu, Y | 1 |
| Soler, A | 1 |
| González-Bals, MJ | 1 |
| Lorente, P | 1 |
| Striano, P | 1 |
| Striano, S | 1 |
| Liedgens, H | 2 |
| Hertel, N | 1 |
| Gabriel, A | 1 |
| Nuijten, M | 2 |
| Dakin, H | 2 |
| Mitchell, S | 1 |
| Nautrup, BP | 2 |
| Chou, R | 1 |
| Carson, S | 1 |
| Chan, BK | 1 |
| Jensen, MP | 3 |
| Chiang, YK | 1 |
| Wu, J | 1 |
| Lopez, PR | 1 |
| Rachael, T | 1 |
| Leicht, S | 1 |
| Smalligan, RD | 1 |
| Kirson, NY | 1 |
| Ivanova, JI | 1 |
| Birnbaum, HG | 1 |
| Wei, R | 1 |
| Kantor, E | 1 |
| Puenpatom, RA | 1 |
| Ben-Joseph, RH | 1 |
| Summers, KH | 1 |
| Irving, G | 2 |
| Cowles, VE | 4 |
| Ong, OL | 1 |
| Churchyard, AC | 1 |
| New, PW | 1 |
| Wolff, RF | 1 |
| Bala, MM | 1 |
| Westwood, M | 1 |
| Kessels, AG | 1 |
| Kleijnen, J | 1 |
| Takasaki, I | 1 |
| Armstrong, EP | 1 |
| Malone, DC | 1 |
| McCarberg, B | 1 |
| Panarites, CJ | 1 |
| Pham, SV | 1 |
| Lapolla, W | 1 |
| Digiorgio, C | 1 |
| Haitz, K | 1 |
| Magel, G | 1 |
| Mendoza, N | 1 |
| Grady, J | 1 |
| Lu, W | 1 |
| Tyring, S | 1 |
| Canafax, DM | 1 |
| Cundy, KC | 1 |
| Ifuku, M | 1 |
| Iseki, M | 1 |
| Hidaka, I | 1 |
| Morita, Y | 1 |
| Komatus, S | 1 |
| Inada, E | 1 |
| Green, CB | 1 |
| Stratman, EJ | 1 |
| Chen, WH | 1 |
| Yin, HL | 1 |
| Thomas, B | 1 |
| Farquhar-Smith, P | 1 |
| Hsu, PH | 1 |
| Vanhove, GF | 3 |
| Sang, CN | 1 |
| Sathyanarayana, R | 1 |
| Chen, C | 3 |
| Beal, B | 1 |
| Moeller-Bertram, T | 1 |
| Schilling, JM | 1 |
| Thakur, R | 1 |
| Philip, AG | 1 |
| Davis, TL | 1 |
| Rauck, RL | 1 |
| Irving, GA | 1 |
| Johnson, P | 1 |
| Becker, L | 1 |
| Halpern, R | 1 |
| Bailey, JM | 1 |
| Vandenkerkhof, EG | 1 |
| Wallace, M | 1 |
| Han, CH | 1 |
| Tenser, RB | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Anderson, HA | 1 |
| Sirinathsinghji, EC | 1 |
| Clapp, RH | 1 |
| Martin, WJ | 1 |
| Kinchington, PR | 2 |
| Krah, DL | 1 |
| Abbadie, C | 1 |
| Fleetwood-Walker, SM | 1 |
| Bookwalter, T | 1 |
| Gitlin, M | 1 |
| Wasner, G | 1 |
| Wareham, D | 1 |
| Chandra, K | 1 |
| Shafiq, N | 1 |
| Pandhi, P | 1 |
| Gupta, S | 1 |
| Malhotra, S | 1 |
| Hasnie, FS | 1 |
| Breuer, J | 1 |
| Parker, S | 1 |
| Wallace, V | 1 |
| Blackbeard, J | 1 |
| Lever, I | 1 |
| Dickenson, AH | 1 |
| Pheby, T | 1 |
| Tarride, JE | 1 |
| Gordon, A | 1 |
| Vera-Llonch, M | 1 |
| Dukes, E | 1 |
| Rousseau, C | 1 |
| Lalonde, RL | 1 |
| Kowalski, KG | 1 |
| Hutmacher, MM | 1 |
| Ewy, W | 1 |
| Nichols, DJ | 1 |
| Milligan, PA | 1 |
| Corrigan, BW | 1 |
| Lockwood, PA | 1 |
| Marshall, SA | 1 |
| Benincosa, LJ | 1 |
| Tensfeldt, TG | 1 |
| Parivar, K | 1 |
| Amantea, M | 1 |
| Glue, P | 1 |
| Koide, H | 1 |
| Miller, R | 1 |
| O'Connor, AB | 1 |
| Noyes, K | 1 |
| Holloway, RG | 1 |
| Gore, M | 1 |
| Sadosky, A | 1 |
| Tai, KS | 1 |
| Stacey, B | 1 |
| Niscola, P | 1 |
| Perrotti, AP | 1 |
| del Poeta, G | 1 |
| Romani, C | 1 |
| Palombi, M | 1 |
| Piccioni, D | 1 |
| Scaramucci, L | 1 |
| Tolu, B | 1 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Abruzzese, E | 1 |
| D'Elia, GM | 1 |
| Brunetti, GA | 1 |
| Maurillo, L | 1 |
| Giovannini, M | 1 |
| Cartoni, C | 1 |
| de Fabritiis, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Randomized Placebo-Controlled Clinical Trial of Preoperative Gabapentin Prior to Vaginal Apical Suspension Prolapse Procedures[NCT05658887] | Phase 4 | 110 participants (Anticipated) | Interventional | 2023-01-01 | Enrolling by invitation | ||
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| Pain Reduction and Changes in Upper Limb Function Produced by Physiotherapy, Ibuprofen Arginine, Gabapentin and the Absence of Treatment, in Carpal Tunnel Syndrome[NCT04025203] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Pain Reduction and Changes in Upper Limb Function Produced by Over the Counter Oral Ibuprofen Versus the Lack of Treatment, in Carpal Tunnel Syndrome.[NCT04328805] | Phase 4 | 45 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Oral Gabapentin Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04285281] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Physical Therapy Versus Control in the Treatment of Carpal Tunnel Syndrome[NCT04329247] | 40 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | |||
| Prophylactic Duloxetine Administration During Acute Herpes Zoster Prevents Postherpetic Neuralgia[NCT04313335] | 750 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | |||
| EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787] | Phase 2 | 77 participants (Anticipated) | Interventional | 2021-10-25 | Recruiting | ||
| Efficacy of Electroacupuncture Therapy in Patients With Postherpetic Neuralgia: a Multicentre Randomised Controlled Trial[NCT04594226] | 132 participants (Actual) | Interventional | 2020-11-11 | Completed | |||
| Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy[NCT03571334] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia[NCT00335933] | Phase 3 | 378 participants (Anticipated) | Interventional | 2006-05-31 | Completed | ||
| A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia[NCT00636636] | Phase 3 | 452 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice[NCT01426230] | 201 participants (Actual) | Observational | 2011-09-30 | Completed | |||
| [NCT01250561] | 133 participants (Actual) | Interventional | 2002-02-28 | Completed | |||
| Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin[NCT01821430] | Phase 2 | 4 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to poor recruitment) | ||
| Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary. Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10). (NCT00636636)
Timeframe: 10 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| G-ER | -2.30 |
| Placebo | -1.59 |
"Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as very much improved (score = 1) or much improved (score = 2)." (NCT00636636)
Timeframe: 10 weeks
| Intervention | Participants (Number) |
|---|---|
| G-ER | 97 |
| Placebo | 78 |
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10). (NCT00636636)
Timeframe: 10 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| G-ER | -2.12 |
| Placebo | -1.63 |
Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in last observation carried forward (LOCF) average daily pain score from baseline to final week of efficacy treatment period (Week 10). (NCT00636636)
Timeframe: 10 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| G-ER | -2.40 |
| Placebo | -1.85 |
"Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as very much improved (score = 1) or much improved (score = 2)." (NCT00636636)
Timeframe: 10 weeks
| Intervention | Participants (Number) |
|---|---|
| G-ER | 94 |
| Placebo | 77 |
"Change from baseline in pain score on visual analog scale (VAS) (intensity scored from No Pain (0mm) to Worst Possible Pain (100mm)) at Week 8 of treatment; last observation carried forward (LOCF) analysis" (NCT01426230)
Timeframe: 8 weeks (Baseline and Week 8)
| Intervention | scores on a scale (Mean) |
|---|---|
| Open Label - Cohort >70 Yrs Old | -20.4 |
| Open Label - Cohort <=70 Yrs Old | -21.3 |
31 reviews available for gabapentin and Postherpetic Neuralgia
| Article | Year |
|---|---|
Efficacy of gabapentinoids for acute herpes zoster in preventing postherpetic neuralgia: a systematic review of randomized controlled trials.
Topics: Analgesics; Gabapentin; Herpes Zoster; Humans; Neuralgia, Postherpetic; Randomized Controlled Trials | 2022 |
Therapeutic Strategies for Postherpetic Neuralgia: Mechanisms, Treatments, and Perspectives.
Topics: Aged; Analgesics; Antidepressive Agents, Tricyclic; Gabapentin; Humans; Lidocaine; Neuralgia, Posthe | 2023 |
Pregabalin and gabapentin for pain.
Topics: Analgesics; Diabetic Neuropathies; Evidence-Based Medicine; Fibromyalgia; Gabapentin; Humans; Neural | 2020 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
Interventions for Neuropathic Pain: An Overview of Systematic Reviews.
Topics: Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexa | 2017 |
A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2018 |
A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
Topics: Analgesics; Diabetic Neuropathies; Drug Approval; Fibromyalgia; Gabapentin; Humans; Low Back Pain; M | 2019 |
Therapeutic options for the treatment of postherpetic neuralgia: a systematic review.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Approval; Gabapentin; gamm | 2013 |
Evidence-based guidance for the management of postherpetic neuralgia in primary care.
Topics: Amines; Analgesics; Capsaicin; Carbamates; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gab | 2013 |
Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2014 |
Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neural | 2014 |
Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Chemistry, Pharmaceutical; Cyclohexanecarboxylic A | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Post-herpetic Neuralgia: a Review.
Topics: Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Evidence-Bas | 2016 |
Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Carbamates; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Hu | 2017 |
Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy.
Topics: Amines; Animals; Anticonvulsants; Calcium Channels, L-Type; Clinical Trials as Topic; Cognition; Cyc | 2008 |
Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials.
Topics: Amines; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gabape | 2009 |
5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review.
Topics: Administration, Cutaneous; Amines; Analgesics; Anesthetics, Local; Clinical Trials as Topic; Cyclohe | 2011 |
[Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia].
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors | 2011 |
Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
Topics: Administration, Topical; Amines; Anesthetics, Local; Antidepressive Agents, Tricyclic; Capsaicin; Cl | 2011 |
Review of current guidelines on the care of postherpetic neuralgia.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Capsaicin; Cyclohexanecarb | 2011 |
Extended-release gabapentin in post-herpetic neuralgia.
Topics: Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Gabapent | 2011 |
Clinical development of a once-daily gastroretentive formulation of gabapentin for treatment of postherpetic neuralgia: an overview.
Topics: Amines; Analgesics; Biological Availability; Chemistry, Pharmaceutical; Cyclohexanecarboxylic Acids; | 2012 |
Gabapentin for once-daily treatment of post-herpetic neuralgia: a review.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Gabapentin; gamm | 2012 |
The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery.
Topics: Amines; Analgesics; Chemistry, Pharmaceutical; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2013 |
Chronic pain perspectives: Treating herpes zoster and postherpetic neuralgia: an evidence-based approach.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antipruritics; Capsaicin; | 2012 |
Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Gastr | 2013 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Amines; Antidepressive Agents, Tricyclic; Antiviral Agents; Arabinofuranos | 2005 |
Model-based drug development.
Topics: Alzheimer Disease; Amines; Analgesics; Animals; Anticholesteremic Agents; Bridged Bicyclo Compounds, | 2007 |
A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Cyclohexanecarbox | 2007 |
18 trials available for gabapentin and Postherpetic Neuralgia
| Article | Year |
|---|---|
Observation and Analysis of Clinical Efficacy of Zhuang Medicine Lotus Acupuncture Cupping Stasis Therapy on Patients with Postherpetic Neuralgia.
Topics: Acupuncture Therapy; beta Catenin; Gabapentin; Humans; Interleukin-18; Lotus; Neuralgia, Postherpeti | 2023 |
Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Gabapentin; Herpes Zoster; Humans; Male; Middl | 2019 |
Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delaye | 2013 |
Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double- | 2015 |
Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids | 2015 |
Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2015 |
Randomized and controlled prospective trials of Ultrasound-guided spinal nerve posterior ramus pulsed radiofrequency treatment for lower back post-herpetic neuralgia.
Topics: Administration, Oral; Adult; Aged; Amines; Amitriptyline; Analgesics; Celecoxib; Cyclohexanecarboxyl | 2015 |
Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study.
Topics: Acetaminophen; Acyclovir; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Non-Narcotic; Ant | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed | 2016 |
Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial.
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Clinical Protocols; Cyclohexanecarboxylic Acids; Do | 2017 |
Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Dose-Response Re | 2009 |
Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study.
Topics: Administration, Oral; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparat | 2010 |
Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.
Topics: Adult; Aged; Amines; Analgesics; Carbamates; Cyclohexanecarboxylic Acids; Double-Blind Method; Femal | 2011 |
Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2012 |
Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN).
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep | 2013 |
Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Amines; Analgesics; Causality; Comorbidity; Cyclohexanecarboxylic Acids; Disorders of Excessive Somn | 2013 |
Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep | 2013 |
Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
Topics: Aged; Amines; Analgesics; Capsules; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; D | 2006 |
36 other studies available for gabapentin and Postherpetic Neuralgia
| Article | Year |
|---|---|
Effect of Repeated High-voltage Long-duration Pulsed Radiofrequency on Herpetic Neuralgia.
Topics: Gabapentin; Galectin 3; Herpes Zoster; Humans; Interleukin-6; Morphine Derivatives; Neuralgia; Neura | 2022 |
Effective treatment of high-voltage pulsed radiofrequency combined with oxygen-ozone injection in acute zoster neuralgia.
Topics: Gabapentin; Herpes Zoster; Humans; Neuralgia; Neuralgia, Postherpetic; Oxygen; Ozone; Pulsed Radiofr | 2022 |
Comparison of therapeutic effects of continuous epidural nerve block combined with drugs on postherpetic neuralgia.
Topics: Acetaminophen; Administration, Oral; Aged; Aged, 80 and over; Analgesia, Epidural; Combined Modality | 2021 |
[Whether or not to use gabapentinoids in adults with chronic neuropathic pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Pain; Diabetic Neuropathies; Female; Gabapentin; | 2020 |
Thermographic follow-up of postherpetic neuralgia (PHN) subsequent to Ramsay Hunt syndrome with multicranial nerve (V, VII, VIII and IX) involvement: a case report.
Topics: Aged; Analgesics; Anesthetics, Local; Follow-Up Studies; Gabapentin; Herpes Zoster Oticus; Humans; L | 2021 |
Efficacy of repetitive paravertebral block combined with medication in the treatment of zoster-related pain with different courses.
Topics: Aged; Analgesics; Combined Modality Therapy; Female; Gabapentin; Humans; Male; Middle Aged; Nerve Bl | 2021 |
Gabapentin for Chronic Neuropathic Pain.
Topics: Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Gabape | 2018 |
Up-date on Clinical Management of Postherpetic Neuralgia and Mechanism-Based Treatment: New Options in Therapy.
Topics: Acetylcholine Release Inhibitors; Analgesics; Antidepressive Agents, Tricyclic; Botulinum Toxins, Ty | 2018 |
Premedication With Gabapentin Significantly Reduces the Risk of Postherpetic Neuralgia in Patients With Neuropathy.
Topics: Antiviral Agents; Diabetic Neuropathies; Female; Gabapentin; Herpes Zoster; Humans; Male; Middle Age | 2019 |
An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population.
Topics: Acetaminophen; Adolescent; Adult; Aged; Amines; Amitriptyline; Analgesics, Non-Narcotic; Analgesics, | 2013 |
Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Topics: Amines; Analgesics; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Femal | 2013 |
Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetic Neuropathi | 2014 |
Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN).
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids | 2015 |
Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gaba | 2015 |
[Shingles symptoms are gone but not the pain].
Topics: Administration, Cutaneous; Administration, Oral; Aged; Amines; Amitriptyline; Analgesics; Anti-Infla | 2015 |
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Topics: Administration, Cutaneous; Amines; Analgesics; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; D | 2008 |
Gabapentin-induced delusions of parasitosis.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delusions; Female; Gabapentin; gamma-Aminobut | 2010 |
Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Topics: Amines; Analgesics; Costs and Cost Analysis; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma- | 2010 |
The importance of early diagnosis of herpes zoster myelitis.
Topics: Acyclovir; Aged; Amines; Analgesics; Anti-Inflammatory Agents; Antiviral Agents; Cyclohexanecarboxyl | 2010 |
Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study.
Topics: Acute Disease; Acyclovir; Aged; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; D | 2011 |
Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy.
Topics: Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma- | 2011 |
Prevent rather than treat postherpetic neuralgia by prescribing gabapentin earlier in patients with herpes zoster: comment on "incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes z
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; ga | 2011 |
Successful amelioration of tinnitus in a stroke patient by low-dose gabapentin.
Topics: Amines; Audiometry, Pure-Tone; Basal Ganglia Hemorrhage; Cerebral Angiography; Cyclohexanecarboxylic | 2012 |
Once-daily gabapentin (Gralise) for postherpetic neuralgia.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Gabapentin; gamma-Ami | 2011 |
Postherpetic neuralgia: treatment strategies for pain control.
Topics: Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Ac | 2012 |
Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin.
Topics: Adolescent; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delivery of Health Care; D | 2013 |
Chronobiological characteristics of neuropathic pain: clinical predictors of diurnal pain rhythmicity.
Topics: Amines; Analgesics; Analysis of Variance; Circadian Rhythm; Cyclohexanecarboxylic Acids; Diabetic Ne | 2013 |
Herpes zoster and the prevention of postherpetic neuralgia: beyond antiviral therapy.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antiviral Agents; Calcium Channels; Clinical Trials as | 2005 |
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2005 |
Gabapentin-induced neurologic toxicities.
Topics: Acute Kidney Injury; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2005 |
Prevention and treatment of postherpetic neuralgia.
Topics: Adult; Amines; Anesthetics, Local; Antiviral Agents; Calcium Channel Blockers; Child, Preschool; Cyc | 2006 |
Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.
Topics: Amines; Analgesics; Animals; Anti-Anxiety Agents; Anxiety Disorders; Cells, Cultured; Cyclohexanecar | 2007 |
Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Topics: Amines; Analgesics; Canada; Clinical Trials as Topic; Costs and Cost Analysis; Cross-Sectional Studi | 2006 |
Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
Topics: Administration, Cutaneous; Aged; Amines; Analgesics; Anesthetics, Local; Cost-Benefit Analysis; Cycl | 2007 |
A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Anticonvulsants; | 2007 |
Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures.
Topics: Acute Disease; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic | 2007 |